Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia

Harvey L. Levy, Susan E. Waisbren, Flemming Güttler, William B. Hanley, Reuben Matalon, Bobbye Rouse, Friedrich K. Trefs, Felix De La Cruz, Colleen G. Azen, Richard Koch

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective. A major issue in maternal phenylketonuria (MPKU) has been whether maternal non-PKU mild hyperphenylalaninemia (MHP) is teratogenic. Such untreated pregnancies and their outcomes are presented on this report. Methods. Enrolled pregnancies in which the untreated prepregnancy assigned phenylalanine level (APL) was no more than 600 μmol/L were included in the Maternal PKU Collaborative Study and were followed according to protocol. Results. Forty-eight enrolled women with non-PKU MHP had mean APL 408 ± 114 μmol/L. They had a total of 58 pregnancies that resulted in live births. Fifty were untreated. Maternal phenylalanine (Phe) levels in the untreated pregnancies decreased during pregnancy for average Phe exposure of 270 ± 84 μmol/L, virtually identical to the level of 269 ± 136 μmol/L in the 8 treated pregnancies. Birth measurements in the 50 offspring from untreated pregnancies were within normal limits with z scores of -0.25 for weight, 0.28 for length, and -0.63 for head circumference, although birth head circumference was negatively correlated with maternal APL (r = -0.30). Only 1 offspring had congenital heart disease. Offspring IQ was 102 ± 15 compared with 96 ± 14 in the mothers with untreated pregnancies and with 109 ± 21 in control offspring. Conclusion. Maternal non-PKU MHP no more than 600 μmol/L does not require dietary therapy. The naturally lower Phe level during pregnancy seems to protect against teratogenesis.

Original languageEnglish (US)
Pages (from-to)1548-1552
Number of pages5
JournalPediatrics
Volume112
Issue number6 II
StatePublished - Dec 2003

Fingerprint

Phenylketonurias
Maternal Phenylketonuria
Phenylalanine
Pregnancy
Mothers
Head
Parturition
Teratogenesis
Live Birth
Pregnancy Outcome
Heart Diseases
Weights and Measures

Keywords

  • Birth head circumference
  • Birth length
  • Birth weight
  • Genotype
  • IQ
  • Maternal phenylalanine
  • Offspring

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Levy, H. L., Waisbren, S. E., Güttler, F., Hanley, W. B., Matalon, R., Rouse, B., ... Koch, R. (2003). Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia. Pediatrics, 112(6 II), 1548-1552.

Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia. / Levy, Harvey L.; Waisbren, Susan E.; Güttler, Flemming; Hanley, William B.; Matalon, Reuben; Rouse, Bobbye; Trefs, Friedrich K.; De La Cruz, Felix; Azen, Colleen G.; Koch, Richard.

In: Pediatrics, Vol. 112, No. 6 II, 12.2003, p. 1548-1552.

Research output: Contribution to journalArticle

Levy, HL, Waisbren, SE, Güttler, F, Hanley, WB, Matalon, R, Rouse, B, Trefs, FK, De La Cruz, F, Azen, CG & Koch, R 2003, 'Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia', Pediatrics, vol. 112, no. 6 II, pp. 1548-1552.
Levy HL, Waisbren SE, Güttler F, Hanley WB, Matalon R, Rouse B et al. Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia. Pediatrics. 2003 Dec;112(6 II):1548-1552.
Levy, Harvey L. ; Waisbren, Susan E. ; Güttler, Flemming ; Hanley, William B. ; Matalon, Reuben ; Rouse, Bobbye ; Trefs, Friedrich K. ; De La Cruz, Felix ; Azen, Colleen G. ; Koch, Richard. / Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia. In: Pediatrics. 2003 ; Vol. 112, No. 6 II. pp. 1548-1552.
@article{4f5357cdba064b5d8a93d954aa592efb,
title = "Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia",
abstract = "Objective. A major issue in maternal phenylketonuria (MPKU) has been whether maternal non-PKU mild hyperphenylalaninemia (MHP) is teratogenic. Such untreated pregnancies and their outcomes are presented on this report. Methods. Enrolled pregnancies in which the untreated prepregnancy assigned phenylalanine level (APL) was no more than 600 μmol/L were included in the Maternal PKU Collaborative Study and were followed according to protocol. Results. Forty-eight enrolled women with non-PKU MHP had mean APL 408 ± 114 μmol/L. They had a total of 58 pregnancies that resulted in live births. Fifty were untreated. Maternal phenylalanine (Phe) levels in the untreated pregnancies decreased during pregnancy for average Phe exposure of 270 ± 84 μmol/L, virtually identical to the level of 269 ± 136 μmol/L in the 8 treated pregnancies. Birth measurements in the 50 offspring from untreated pregnancies were within normal limits with z scores of -0.25 for weight, 0.28 for length, and -0.63 for head circumference, although birth head circumference was negatively correlated with maternal APL (r = -0.30). Only 1 offspring had congenital heart disease. Offspring IQ was 102 ± 15 compared with 96 ± 14 in the mothers with untreated pregnancies and with 109 ± 21 in control offspring. Conclusion. Maternal non-PKU MHP no more than 600 μmol/L does not require dietary therapy. The naturally lower Phe level during pregnancy seems to protect against teratogenesis.",
keywords = "Birth head circumference, Birth length, Birth weight, Genotype, IQ, Maternal phenylalanine, Offspring",
author = "Levy, {Harvey L.} and Waisbren, {Susan E.} and Flemming G{\"u}ttler and Hanley, {William B.} and Reuben Matalon and Bobbye Rouse and Trefs, {Friedrich K.} and {De La Cruz}, Felix and Azen, {Colleen G.} and Richard Koch",
year = "2003",
month = "12",
language = "English (US)",
volume = "112",
pages = "1548--1552",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6 II",

}

TY - JOUR

T1 - Pregnancy Experiences in the Woman with Mild Hyperphenylalaninemia

AU - Levy, Harvey L.

AU - Waisbren, Susan E.

AU - Güttler, Flemming

AU - Hanley, William B.

AU - Matalon, Reuben

AU - Rouse, Bobbye

AU - Trefs, Friedrich K.

AU - De La Cruz, Felix

AU - Azen, Colleen G.

AU - Koch, Richard

PY - 2003/12

Y1 - 2003/12

N2 - Objective. A major issue in maternal phenylketonuria (MPKU) has been whether maternal non-PKU mild hyperphenylalaninemia (MHP) is teratogenic. Such untreated pregnancies and their outcomes are presented on this report. Methods. Enrolled pregnancies in which the untreated prepregnancy assigned phenylalanine level (APL) was no more than 600 μmol/L were included in the Maternal PKU Collaborative Study and were followed according to protocol. Results. Forty-eight enrolled women with non-PKU MHP had mean APL 408 ± 114 μmol/L. They had a total of 58 pregnancies that resulted in live births. Fifty were untreated. Maternal phenylalanine (Phe) levels in the untreated pregnancies decreased during pregnancy for average Phe exposure of 270 ± 84 μmol/L, virtually identical to the level of 269 ± 136 μmol/L in the 8 treated pregnancies. Birth measurements in the 50 offspring from untreated pregnancies were within normal limits with z scores of -0.25 for weight, 0.28 for length, and -0.63 for head circumference, although birth head circumference was negatively correlated with maternal APL (r = -0.30). Only 1 offspring had congenital heart disease. Offspring IQ was 102 ± 15 compared with 96 ± 14 in the mothers with untreated pregnancies and with 109 ± 21 in control offspring. Conclusion. Maternal non-PKU MHP no more than 600 μmol/L does not require dietary therapy. The naturally lower Phe level during pregnancy seems to protect against teratogenesis.

AB - Objective. A major issue in maternal phenylketonuria (MPKU) has been whether maternal non-PKU mild hyperphenylalaninemia (MHP) is teratogenic. Such untreated pregnancies and their outcomes are presented on this report. Methods. Enrolled pregnancies in which the untreated prepregnancy assigned phenylalanine level (APL) was no more than 600 μmol/L were included in the Maternal PKU Collaborative Study and were followed according to protocol. Results. Forty-eight enrolled women with non-PKU MHP had mean APL 408 ± 114 μmol/L. They had a total of 58 pregnancies that resulted in live births. Fifty were untreated. Maternal phenylalanine (Phe) levels in the untreated pregnancies decreased during pregnancy for average Phe exposure of 270 ± 84 μmol/L, virtually identical to the level of 269 ± 136 μmol/L in the 8 treated pregnancies. Birth measurements in the 50 offspring from untreated pregnancies were within normal limits with z scores of -0.25 for weight, 0.28 for length, and -0.63 for head circumference, although birth head circumference was negatively correlated with maternal APL (r = -0.30). Only 1 offspring had congenital heart disease. Offspring IQ was 102 ± 15 compared with 96 ± 14 in the mothers with untreated pregnancies and with 109 ± 21 in control offspring. Conclusion. Maternal non-PKU MHP no more than 600 μmol/L does not require dietary therapy. The naturally lower Phe level during pregnancy seems to protect against teratogenesis.

KW - Birth head circumference

KW - Birth length

KW - Birth weight

KW - Genotype

KW - IQ

KW - Maternal phenylalanine

KW - Offspring

UR - http://www.scopus.com/inward/record.url?scp=0348014935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348014935&partnerID=8YFLogxK

M3 - Article

C2 - 14654663

AN - SCOPUS:0348014935

VL - 112

SP - 1548

EP - 1552

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6 II

ER -